These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9059545)

  • 1. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale.
    Kiely DG; Cargill RI; Wheeldon NM; Coutie WJ; Lipworth BJ
    Cardiovasc Res; 1997 Jan; 33(1):201-8. PubMed ID: 9059545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade.
    Kiely DG; Cargill RI; Lipworth BJ
    Cardiovasc Res; 1995 Dec; 30(6):875-80. PubMed ID: 8746201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
    Morrell NW
    Chest; 1997 May; 111(5):1469-70. PubMed ID: 9149625
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
    Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
    Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
    Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
    Crozier I; Ikram H; Awan N; Cleland J; Stephen N; Dickstein K; Frey M; Young J; Klinger G; Makris L
    Circulation; 1995 Feb; 91(3):691-7. PubMed ID: 7828295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of losartan, the first angiotensin II receptor antagonist.
    Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
    Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
    Baan J; Chang PC; Vermeij P; Pfaffendorf M; van Zwieten PA
    Cardiovasc Res; 1996 Nov; 32(5):973-9. PubMed ID: 8944829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
    Gansevoort RT; de Zeeuw D; Shahinfar S; Redfield A; de Jong PE
    J Hypertens Suppl; 1994 Jul; 12(2):S37-42. PubMed ID: 7965264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
    Smith MC; Barrows S; Meibohm A; Shahinfar S; Simpson RL; Weigel K; Dunn MJ
    Am J Hypertens; 1995 Dec; 8(12 Pt 1):1177-83. PubMed ID: 8998251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
    Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
    Arch Mal Coeur Vaiss; 1994 Aug; 87(8):971-4. PubMed ID: 7755474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor antagonists.
    Goldsmith DJ
    Lancet; 1997 Apr; 349(9060):1255. PubMed ID: 9130973
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
    Hagino T; Abe K; Tsunoda K; Yoshinaga K
    Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.